Product_Sheet_HNO97-cell_line.pdf

The HNO97 cell line is derived from an oral squamous cell carcinoma, a subtype of head and neck squamous cell
carcinoma (HNSCC). This cell line has been characterized by various chromosomal abnormalities, including DNA
copy number gains in regions such as 3p25-pter, 3q, 5p, 9q22-qter, 10p, 10q, 11cen-p14, 20p, and 20q, alongside
a significant copy number loss in the 18q region. These genetic alterations are consistent with those frequently
observed in aggressive forms of HNSCC and are associated with key oncogenes involved in tumor progression,
including those implicated in cell cycle regulation and proliferation.
HNO97 has been extensively used in studies focused on tumor-specific targeting and peptide binding. For
instance, the HNO97 cell line was instrumental in the identification and characterization of the HBP-1 peptide,
which binds specifically to HNSCC cells and shows potential for use in targeted therapies. The binding kinetics of
HBP-1 to HNO97 cells revealed rapid internalization, making this cell line a valuable model for investigating the
efficacy of novel therapeutic agents aimed at specific molecular targets within HNSCC tumors .
Furthermore, HNO97 has been utilized in biodistribution studies using tumor-bearing nude mice, where it was
shown that certain peptides, like HBP-1, preferentially accumulate in HNO97 tumors, highlighting its utility in
preclinical models for drug delivery and imaging studies. This cell line's genetic and molecular profile makes it
an important tool in the study of oral cancer biology and the development of targeted treatments .